(Q44399396)

2 December 2017

title

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles (English)

1 reference

2 December 2017

0 references

11

Allan Hildesheim

1 reference

2 December 2017

1

Ligia A Pinto

1 reference

2 December 2017

Raphael Viscidi

2

1 reference

2 December 2017

Clayton D Harro

3

1 reference

2 December 2017

Troy J Kemp

4

1 reference

2 December 2017

Alfonso J García-Piñeres

5

1 reference

2 December 2017

Matthew Trivett

6

1 reference

2 December 2017

Franklin Demuth

7

1 reference

2 December 2017

Douglas R Lowy

8

1 reference

2 December 2017

John T Schiller

9

1 reference

2 December 2017

Jay A Berzofsky

10

1 reference

2 December 2017

language of work or name

English

0 references

publication date

24 July 2006

1 reference

2 December 2017

1 reference

2 December 2017

volume

353

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

451-462

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

L1-specific protection from tumor challenge elicited by HPV16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Natural history of cervicovaginal papillomavirus infection in young women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Immunological memory to viral infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

HPV6b virus like particles are potent immunogens without adjuvant in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

7 January 2021

On immunological memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.06.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2006.06.021

1 reference

2 December 2017

1 reference